The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

G protein-coupled receptors (GPCRs) play a central role in the pathogenesis and development of osteoporosis, a serious bone metabolism-related disease.

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

LUT014, a topical BRAF-inhibiting gel, may mitigate acneiform rash in patients receiving EGFR-targeted therapy for colorectal cancer, according to phase II clinical trial results presented by Anisha B ...